What We Do

Our “protection pill,” NHPN-1010, is one of our therapeutic technologies and represents a potential and hopeful answer to noise or blast-induced hearing loss. Possible indications for NHPN-1010 include, but are not limited to, noise-induced hearing loss, blast-induced hearing loss, tinnitus, hyperacusis, and protection from degenerative hearing loss.

The pill has passed Phase I clinical trials for safety and was found to be safe and well-tolerated. The next steps are for a pharmaceutical company to further clinical development through Phase III clinical trials for each indication.

Hough Ear Institute cannot provide updates on the clinical development status of NHPN-1010. All inquiries should be directed to Elaine Hamm at ehamm@ascendbioventures.com.